

32nd Annual Cancer Progress Conference, May 4th – 6th 2021

May 4, 2021

9:00 – 9:15 am

Opening Remarks

Jeffrey M. Bockman, PhD, EVP, Head of Oncology Practice, Cello Health BioConsulting

9:15 – 10:00 am

Keynote: Engineering the Future: Next Gen Platforms in Oncology

Speaker: Daniel S Chen, MD, PhD, Chief Medical Officer, IGM Biosciences

10:15 – 11:30 am

Climbing the Highest Peak: Targeting PD-1/L1 Failures in Solid Tumors

Moderator: Jeffrey M. Bockman, PhD, EVP, Oncology Practice Head, and James T. Lee, PhD, Principal, Oncology Lead, Cello Health BioConsulting

Panelists:

- Neil Brewis, PhD, Chief Scientific Officer, F-star Therapeutics
- Michael A Curran, PhD, Associate Professor, Dept. of Immunology
Founder, ImmunoGenesis, Inc, The University of Texas MD Anderson Cancer Center, Department of Immunology, Division of Basic Sciences
- Kapil Dhingra, MD, Managing Member, KAPital Consulting LLC
- Laurent Levy, PhD, CEO Nanobiotix
- Thomas Schuetz, MD, PhD, CEO and Co-founder, Compass Therapeutics
- Emmett Schmidt, MD, PhD, Associate Vice President, Clinical Oncology & Lead, External Collaborations, Merck Research Laboratories
- Mai-Britt Zocca, PhD, CEO, IO Biotech

11:45 am – 1:00 pm

Multifunctional Soluble Biologics: Binders, Binders Everywhere

Moderator: James T. Lee, PhD, Principal, Oncology Lead, and Serom Lee, PhD, Consultant, Cello Health BioConsulting

Panelists:

- Philip Bland-Ward, PhD, Chief Development Officer, Crescendo Biologics Ltd
- Alicia Chung, PhD, Corporate Development, Amphivena Therapeutics Inc
- Eliot Forster, BSc, PhD, MBA, FRSA, Chief Executive Officer, F-star Therapeutics
- Björn Frendeus, Chief Scientific Officer, BioInvent International AB
- Valerie Odegard, PhD, CSO, Silverback Therapeutics
- Taylor H. Schreiber, MD, PhD, Chief Executive Officer Shattuck Labs, Inc

1:00 - 1:30 pm

Break for Lunch



cellohealthbioconsulting.com



cellohealth.com



cancerprogressbycellohealth.com

1:30 – 2:45 pm

Tumor Agnostic Development

- **Moderator** Julie R. Gralow, M.D., FACP, FASCO, Executive Vice President and Chief Medical Officer, American Society of Clinical Oncology Association for Clinical Oncology

Panelists:

- David Hyman MD, Chief Medical Officer, Loxo Oncology at Lilly
- Brian Leyland Jones, MB BS, PhD, CMO, National Foundation For Cancer Research
- Jean-François Martini, Ph.D., M.Sc., Sr. Director, Translational Oncology Lead, Global Product Development, Pfizer Inc
- Mark Pegram, MD, Professor of Medical Oncology, Stanford Comprehensive Cancer Institute, Stanford University
- Richard L. Schilsky, M.D., FACP, FSCT, FASCO, Professor Emeritus, University of Chicago

3:00 – 4:15 pm

Accelerated Development Paths

Moderator: Brian Leyland Jones, MB BS, PhD, CMO, National Foundation For Cancer Research

Panelists:

- Nora Ku, MD, VP, Medical, Loxo Oncology at Lilly
- Ralph E. Parchment, PhD, Managing Director, DCTD Program in Pharmacodynamic Biomarkers, NCI
- Professor Paul Workman, Chief Executive and President, The Institute of Cancer Research, London

4:30 – 5:45 pm

Endogenous Reprogramming: Anything One Can Do Ex Vivo, Can One Do In Vivo (and Do Better)?

Moderator: Jeffrey M. Bockman, PhD, EVP, Head of Oncology Practice, Cello Health BioConsulting

Panelists:

- Jacob Becraft, PhD, CEO, Co-founder, Strand Therapeutics
- Nicholas A. Boyle, PhD, MBA, CEO, Abintus Bio
- Mary Haak-Frendscho, PhD, President & CEO, Spotlight Therapeutics
- Stephan Matthias, MD PhD, Associate Professor, Clinical Research Division, Fred Hutchinson Cancer Center

5:45 pm

Day 1 Cancer Progress 2021 Conference Conclude

May 5, 2021

9:00 – 9:15 am

Opening Remarks: Review of Day 1

Michael C. Rice, MS, MBA, VP, Head of Advanced Therapeutics, Cello Health BioConsulting

9:15- – 10:00 am

Keynote Address: Off-the-shelf CAR-engineered NK cells for the treatment of cancer

Speaker: Katy Rezvani, MD, PhD, Sally Copper Murray Endowed Chair in Cancer Research Professor of Medicine, Chief, Section of Cellular Therapy, Director for Translational Research Medical Director, SCT Laboratory and the GMP Laboratory, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center

10:15- 11:30 am

Allogeneic Cell Therapy: Stocking the Shelf Part I (NKs, NKTs)

Moderator: Michael C. Rice, MS, MBA, VP, Head of Advanced Therapeutics, Cello Health BioConsulting

Panelists

- Kurt Gunter, MD, Chief Medical Officer, kuur Therapeutics
- Kaouthar Lbiati, MD, Vice President, Corporate Strategy, Cytovia Therapeutics
- Jason B. Litten, MD, Chief Medical Officer, Artiva Biotherapeutics, Inc., Artiva Biotherapeutics
- Annemarie Moseley, MD PhD, CEO, Sandhill Therapeutics
- Kelly Page, Global Head of Cell Therapy Commercialization of Cell Therapy Commercialization, Takeda Oncology
- Alan Trounson, MSc, PhD, CEO and Executive Director Cartherics

11:45- 1:00 pm

Allogeneic Cell Therapy: Stocking the Shelf Part II (Traditional T-cells, Gamma-deltas)

Moderator: Michael C. Rice, MS, MBA, Principal, Cello Health BioConsulting

Panelists:

- Greg Block, PhD, SVP Corporate Development, Notch Therapeutics
- Rachel Haurwitz, PhD, Chief Executive Officer and Founder Caribou Biosciences, Inc.
- Sandy Hayes, PhD, Senior Director, T cell Immunology/Translational Medicine, Adicet Therapeutics Aija Hrle, PhD, Director, Head of Strategic Alliances, Immatics Biotechnologies

1:00 – 1:30 pm

Break for Lunch

1:30 – 2:45 pm

Cell Therapy in Solid Tumors: Freedom of the Open Road

Moderator: Joel S. Sandler, PhD, Principal, Cancer Cell Therapy Lead, Cello Health BioConsulting

Panelists:

- Sharon Benzeno, SVP, Drug Discovery, Adaptive Biotechnologies Corp.
- John Delyani, PhD, MBA VP, Corporate Development, Tminuty Therapeutics Inc
- Mythili Koneru, MD, PhD, Chief Medical Officer, Marker Therapeutics
- Peter Sandor, MD, MBA, Senior Vice President, Primary Focus Lead Immuno-oncology, Astellas
- Helen Tayton-Martin, PhD, MBA, Chief Business Officer, Adaptimmune **LLC**
- Paul Wotton, PhD, CEO, Obsidian Therapeutics, Inc.

3:00- 4:15 pm

Validating New Platforms: Clinical Pain, Commercial Gain

Moderator: Joel S. Sandler, PhD, Principal, Cancer Cell Therapy Lead, Cello Health BioConsulting

Panelists:

- Robert Ang, MD, MBA, President & CEO, Vor Bio Pharm
- Debora Barton, MD, Chief Medical Officer, Carisma Therapeutics Inc.
- Lawrence Lamb, PhD, Scientific Co-Founder & Chief Scientific Officer, in8bio
- Jan ter Meulen, MD, PhD, CSO, Obsidian Therapeutics, Inc.
- Dan Shoemaker, PhD, Chief Scientific Officer, Fate
- Arndt Schottelius, MD, PhD, Chief Scientific Officer, Affimed

4:30-5:45 pm

Counterpoint to Over-engineering: Bauhaus Minimalism in an Era of More Opulent T-cell Architecture

Moderator: Michael C. Rice, MS, MBA, VP, Head of Advanced Therapeutics, Cello Health BioConsulting

Panelists:

- Keith Bahjat, Sr Director Science, Cell Therapy Center of Excellence, Astellas
- Frank Borriello, MD, PhD, Founder & Chief Executive Officer, Alloplex Biotherapeutics
- Sabine Chlosta, MD, Chief Medical Officer, Triumvera
- Kimberly Noonan, PhD, Founder, EVP & Chief Scientific Officer WindMIL
- Paul D. Rennert, President & Chief Scientific Officer, Aleta Biotherapeutics
- Immatics, TBD

Day 2 Cancer Progress 2021 Conference Concludes

May 6, 2021

8:15 – 8:30 am

Opening Remarks: Review of Day 2

8:30 – 9:45 am

China Panel

Moderator: James T. Lee, PhD, Principal, Oncology Lead, Cello Health BioConsulting

Panelists:

- Fernando Salles, PhD, SVP, Head of US & EU BD, I-Mab Biopharma
- Guillaume Vignon, SVP, BD, BeiGene

10:00- 11:15 am

Investing in the *Emerald City* of Oncology Innovation: Platforms & Modalities & Targets, Oh My!

Moderator: Mark Simon, Partner and Co-Founder, Torreyia

Panelists:

- Margarita Chavez, JD, Managing Director, AbbVie Ventures (tentative)
- Maha Katabi, PhD, CFA, General Partner, Sofinnova Investments
- Carolyn Ng, Director, Vertex Ventures
- Anna Turetsky, Principal, Venture Investments, The Mark Foundation

11:30 am - 12:45 pm

Heme Malignancies Transformed: An Idiosyncratic Comparison of Multiple Myeloma and AML

Moderator: Michael C. Rice, MS, MBA, VP, Head of Advanced Therapeutics, Cello Health BioConsulting

Panelists:

- Kenneth C. Anderson, MD, Dana-Farber Cancer Institute
- Lee Greenberger, MD, PhD, SVP & CSO, Leukemia & Lymphoma Society
- Daniel A Pollyea, MD MS, Associate Professor of Medicine, Division of Hematology, University of Colorado School of Medicine

12:45- 1:15 pm

Break for Lunch

1:30 - 2:45 pm

Let's Make a Deal in Oncology: What's Behind the Doors & Who Has the Keys?

Moderator: Jeremy Goldberg, Operating Partner, Arsenal Capital Partners

Panelists:

- Deepa Talpade, PhD, Head of BD&L Oncology, Bayer
- John DeYoung, VP, Worldwide BD, Oncology Business Unit, Pfizer Inc.
- Philippe Lopes-Fernandes, Executive Vice President, Chief Business Officer, Ipsen
- Christopher Mortko, Associate VP, Business Development and Licensing, Merck & Co., Inc
- Peter Sandor, MD, MBA, Senior Vice President, Primary Focus Lead Immuno-oncology, Astellas

3:00- 4:15 pm

Value Panel

Moderators: Ed Saltzman, Executive Chairman, Cello Heath BioConsulting

Panelists:

- Ron Akehurst, Chairman, BresMed
- Peter Bach, MD, MAPP, Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center
- Michael Kolodziej, MD, VP and CIO, ADVI Health
- Leonard Saltz, MD, Executive Director for Clinical Value & Sustainability; Head, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center

4:30 – 5:30pm

Battle of the Modalities- The sequel

- Jeffrey M. Bockman, PhD, EVP, Head of Oncology Practice, Cello Health BioConsulting
- James T. Lee, PhD, Principal, Oncology Lead Cello Health BioConsulting
- Michael C. Rice, MS, MBA, VP, Head of Advanced Therapeutics, Cello Health BioConsulting
- Joel S. Sandler, PhD, Principal, Cancer Cell Therapy Lead, Cello Health BioConsulting

Cancer Progress 2021 Conference Concludes